A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...

Melanoma is the deadliest form of skin cancer. A new vaccine-drug combo could slash recurring cases - An estimated 112,000 ...

Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...